Janux Therapeutics (JANX) Research & Development (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Research & Development data on file, last reported at $26.8 million in Q1 2026.

• On a quarterly basis, Research & Development rose 7.02% year-over-year to $26.8 million in Q1 2026; TTM through Mar 2026 was $127.7 million, a 60.83% increase from a year earlier, with the FY2025 full-year figure at $125.9 million, up 84.09% from the prior year.
• Research & Development for Q1 2026 stood at $26.8 million, down from $31.5 million in the prior quarter.
• Over the last five years, Research & Development for JANX reached as high as $34.7 million in Q2 2025 and fell as low as $10.2 million in Q1 2022.
• Historically, Research & Development has averaged $19.4 million across 5 years, with a median of $15.4 million in 2022.
• Across the five-year window, Research & Development jumped 429.04% in 2022 and slipped 20.69% in 2023, its largest moves.
• Year by year, Research & Development stood at $15.4 million in 2022, then declined by 20.69% to $12.2 million in 2023, then jumped by 69.97% to $20.8 million in 2024, then jumped by 51.63% to $31.5 million in 2025, then decreased by 15.01% to $26.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $26.8 million in Q1 2026, $31.5 million in Q4 2025, and $34.6 million in Q3 2025.